FCGR2B and neoplasm: Further consistent with tumor B cell expressed FcγRIIB limiting antibody therapeutic efficacy and promoting antibody resistance, retrospective clinical studies of MCL and FL patients treated with rituximab-containing therapy showed decreased survival of patients with higher FcγRIIB expression on tumor cells (67, 69).